Using CAR T cell therapy to treat severe allergic diseases.
Official title: Chimeric antigen receptor (CAR) T cell therapy for severe allergic diseases.
Funded at Cellergy Pharma · NIH-10822618 · Data updated 2026-11-12
This study is exploring a new way to help people with severe allergies by using a special treatment called CAR T cell therapy, which could provide lasting relief from allergy symptoms with just one treatment, instead of relying on medications that can have unwanted side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cellergy Pharma NIH-funded |
| Lab location | 1 site (Wilmington, UNITED STATES) |
| Project start | January 5, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 1R41AI177157-01A1 |
| Project ID | NIH-10822618 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who suffer from severe allergic conditions such as asthma, food allergies, or chronic urticaria.
✕Less likely to help
Patients with mild allergic conditions or those who do not meet the age requirement may not benefit from this research.
What this research studies
This research investigates the use of chimeric antigen receptor (CAR) T cell therapy as a potential treatment for severe allergic diseases, which affect millions of Americans. The approach involves modifying T cells to target and eliminate the underlying causes of allergic reactions, aiming for long-term symptom relief with a single treatment. By leveraging the success of CAR T cell therapy in cancer treatment, this study seeks to provide a novel solution for patients who currently rely on corticosteroids and other long-term therapies that have significant side effects.
Why it matters
Potential benefit: If successful, this research could provide a long-lasting treatment option for patients suffering from severe allergic diseases, potentially reducing their reliance on corticosteroids and improving their quality of life.
How similar studies have gone: While CAR T cell therapy has shown remarkable success in treating certain cancers, its application in severe allergic diseases is novel and has not been extensively tested.
Where this research is happening
-
Cellergy Pharma
Wilmington, United States Active
Researchers
- Principal investigator: Ma, Zhengyu — Cellergy Pharma
- Study coordinator: Ma, Zhengyu
Related research
Other NIH-funded projects on the same topics.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.